Retina Synthesis

We discuss the promising phase I results of the Helios trial studying AXPAXLI TKI inhibitor implant for diabetic retinopathy with Dr. Dilsher Dhoot of California Retina Consultants.

We discuss the use of non steroidal inflammatory agents in the management of central serous chorioretinopathy with Dr. Michael Singer of San Antonio, Texas

We discuss remarkable preliminary results from the the use of intravitreal EYE-103, a novel Wnt pathway agonist in the treatment of DME and neovascular AMD with Dr. Charles Wykoff of Houston Texas.

We discuss the first interim results of a novel intravitreal gene therapy agent, 4D-150, with Dr. Arshad Khanani of Sierra Eye Associates and the University of Nevada Reno School of Medicine.

We discuss the use of a novel bispecific anti-VEGF Anti IL-6 Antibody Biopolymar Conjugate for the treatment of DME with Dr. Mark R. Barakat of Phoenix, AZ.

We discuss the occurrence of retinal vasculitis following pegcetcoplan therapy of geographic atrophy with Dr. Andrew Witkin of the New England Eye Center, Tufts University School of Medicine

We discuss the treatment results of high dose aflibercept in the eyes in the most severe quartile of diabetic macular edema with Dr. Roger Goldberg of Walnut Creek, California.

We discuss the use of an IL-6 inhibitor in the treatment of uveitis macular edema with Dr. Sumit Sharma of the Cole Eye Institute, Cleveland Clinic.

We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.

We discuss the unique results of the Annexon geographic atrophy Phase I clinical trial with Dr. Roger Goldberg of Bay Area Retina Associates, Walnut Creek, California